Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms)*: Fundamentals and Salient Clinical Practice Points for Medical Oncologists
dc.contributor.author | Basu, Sandip | |
dc.contributor.author | Parghane, R. | |
dc.contributor.author | Ranade, R. | |
dc.contributor.author | Thapa, P. | |
dc.date.accessioned | 2020-10-05T09:14:54Z | |
dc.date.available | 2020-10-05T09:14:54Z | |
dc.date.issued | 2019 | |
dc.description.division | RMC | en |
dc.format.extent | 4893 bytes | |
dc.format.mimetype | text/html | |
dc.identifier.source | Indian Journal of Medical and Paediatric Oncology, 2019. Vol. 40 (2): pp. 165-171 | en |
dc.identifier.uri | http://hdl.handle.net/123456789/20737 | |
dc.language.iso | en | en |
dc.subject | Neuroendocrine tumor | en |
dc.subject | neuroendocrine neoplasm | en |
dc.subject | peptide receptor radionuclide therapy (PRRT) | en |
dc.subject | Somatostatin receptor imaging | en |
dc.subject | 68Ga-DOTATATE PET-CT | en |
dc.subject | 99mTc-HYNIC-TOC SPECT | en |
dc.subject | FDG-PET/CT | en |
dc.subject | 177Lu-DOTATATE | en |
dc.subject | 90Y-DOTATOC | en |
dc.title | Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms)*: Fundamentals and Salient Clinical Practice Points for Medical Oncologists | en |
dc.type | Article | en |